Source:http://linkedlifedata.com/resource/pubmed/id/14608538
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2003-11-10
|
pubmed:abstractText |
Myxofibrosarcoma/myxoid malignant fibrous histiocytoma (MFH) has continued to be considered a distinct entity even after recently published reassessments of pleomorphic sarcomas and MFH. Several cell cycle-regulated proteins have already been screened by immunohistochemistry with the aim of finding the reliable prognostic indicator of soft tissue sarcomas; however, it is still unknown whether their altered expression affects patient survival in myxofibrosarcoma. In this study, we evaluated the expression of p53, MDM2, MIB-1 (Ki-67), p21, p27, p16, cyclin A, cyclin D1, and cyclin E by immunohistochemistry in 45 cases of myxofibrosarcoma. First, we searched for possible clinicopathologic prognostic factors in 61 cases of myxofibrosarcoma for which follow-up data were available. In univariate analysis, large tumor size (> or =5 cm), deeply situated tumor, and high histological grade (grade 2 or 3) significantly decreased survival (log-rank test, P <0.05). Among 43 cases of myxofibrosarcoma for which immunohistochemical findings were available, high MIB-1 labeling index (LI) (cutoffs of 10 and 22.5 on average), high cyclin A LI (cutoffs 10% and 13.8% on average), low p21 LI (cutoffs 10 and 20.7 on average), and reduced abnormal expression of p16 were adverse prognostic factors. In multivariate analysis (Cox proportional hazards model), high mitotic rate (>15/10 high-power fields), p53 immunoreactivity (cutoff 10%), high MIB-1 LI (>22.5), low p21 LI (<20.7), and low p27 LI (<47.8 on average) were independent poor prognostic factors. Our results suggest that reduced expression of p21 could be considered a new parameter to be evaluated, along with classical clinicopathologic prognostic factors, for identifying those at high risk for myxofibrosarcoma.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0046-8177
|
pubmed:author |
pubmed-author:IwamotoYukihideY,
pubmed-author:KawaguchiKenichiK,
pubmed-author:KinukawaNaokoN,
pubmed-author:MatsudaShuichiS,
pubmed-author:OdaYoshinaoY,
pubmed-author:TakahiraTomonariT,
pubmed-author:TamiyaSadafumiS,
pubmed-author:TanakaKazuhiroK,
pubmed-author:TsuneyoshiMasazumiM,
pubmed-author:YamamotoHidetakaH
|
pubmed:issnType |
Print
|
pubmed:volume |
34
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1035-42
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:14608538-Adult,
pubmed-meshheading:14608538-Aged,
pubmed-meshheading:14608538-Aged, 80 and over,
pubmed-meshheading:14608538-Cell Cycle Proteins,
pubmed-meshheading:14608538-Female,
pubmed-meshheading:14608538-Fibrosarcoma,
pubmed-meshheading:14608538-Humans,
pubmed-meshheading:14608538-Immunoenzyme Techniques,
pubmed-meshheading:14608538-Male,
pubmed-meshheading:14608538-Middle Aged,
pubmed-meshheading:14608538-Neoplasm Recurrence, Local,
pubmed-meshheading:14608538-Neoplasm Staging,
pubmed-meshheading:14608538-Prognosis,
pubmed-meshheading:14608538-Proportional Hazards Models,
pubmed-meshheading:14608538-Soft Tissue Neoplasms,
pubmed-meshheading:14608538-Survival Rate
|
pubmed:year |
2003
|
pubmed:articleTitle |
Altered expression of cell cycle regulators in myxofibrosarcoma, with special emphasis on their prognostic implications.
|
pubmed:affiliation |
Department of Anatomic Pathology, Graduate School of Medical Information Science, Kyushu University, Fukuoka, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|